Tag Archives: relapsed chronic lymphocytic leukemia

Novartis: Arzerra significantly improves median progression-free survival when added to fludarabine + cyclophosphamide after initial treatment stopped working in patients with relapsed chronic lymphocytic leukemia

Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus existing CLL treatments also had a higher overall response rate (84% vs 68%) compared to … Read the full press release